MedTrace Logo

68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer

NCT02488070 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2018-03-20

Study results available
· View outcomes & findings →

Summary

This clinical trial studies gallium-68 (68Ga)-prostate specific membrane antigen (PSMA) (gallium Ga 68-labeled PSMA ligand Glu-urea-Lys\[Ahx\]) positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) in identifying prostate cancer that may have returned after a period of improvement (biochemical recurrence). 68Ga-PSMA is a radiopharmaceutical that localizes to a specific prostate cancer receptor, which can then be imaged by the PET/CT or PET/MRI scanner.

Conditions

  • Recurrent Prostate Carcinoma

Interventions

PROCEDURE

Computed Tomography

Part of PET/CT scan

DRUG

Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx)

Intravenously-administered (IV) radioisotope

PROCEDURE

Magnetic Resonance Imaging

Part of PET/MRI scan

PROCEDURE

Positron Emission Tomography

Part of PET/CT and/or PET/MRI scans

Sponsors & Collaborators

Principal Investigators

  • Andrei Iagaru · Stanford Cancer Institute

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2015-08-31
Completion
2016-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02488070 on ClinicalTrials.gov